Clinical Trials

ESSA is conducting a monotherapy Phase 1 open-label clinical trial evaluating EPI-7386, an investigational first-in-class N-terminal domain androgen receptor inhibitor, for the treatment of adult patients with castration-resistant prostate cancer (CRPC) resistant to standard-of-care treatments.

ESSA is conducting a combination Phase 1/2 clinical trial evaluating EPI-7386 + enzalutamide in mCRPC patients who have not yet been treated with second-generation antiandrogen therapies.